BML Capital Management LLC Boosts Holdings in Eliem Therapeutics, Inc. (NASDAQ:ELYM)

BML Capital Management LLC boosted its position in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) by 12.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,180,000 shares of the company’s stock after acquiring an additional 241,737 shares during the quarter. Eliem Therapeutics accounts for approximately 4.4% of BML Capital Management LLC’s investment portfolio, making the stock its 6th biggest holding. BML Capital Management LLC owned approximately 7.91% of Eliem Therapeutics worth $5,886,000 at the end of the most recent reporting period.

Separately, Cerity Partners LLC bought a new stake in Eliem Therapeutics during the fourth quarter worth $37,000. Hedge funds and other institutional investors own 69.76% of the company’s stock.

Eliem Therapeutics Price Performance

NASDAQ:ELYM opened at $3.75 on Wednesday. Eliem Therapeutics, Inc. has a one year low of $2.34 and a one year high of $5.19. The company has a market cap of $103.95 million, a P/E ratio of -2.55 and a beta of 0.51. The firm’s fifty day moving average price is $3.00 and its two-hundred day moving average price is $2.78.

About Eliem Therapeutics

Eliem Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial.